BDTX on Nasdaq
Black Diamond Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with VIR Biotechnology, Compugen Ltd. or Cellectis, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development48¢$33.6M
- Other costs20¢$14.1M
- Profit32¢$22.4M
Out of $70.0M in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$29.6M
Out of $29.6M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| License revenue | $70.0M | $0 |
| Research and development | $33.6M | $51.3M |
| General and administrative | $16.6M | $27.5M |
| Impairment of right-of-use assets and property and equipment | $7.3M | $0 |
| Total operating expenses | $57.5M | $78.8M |
| Income (loss) from operations | $12.5M | -$78.8M |
| Interest income | $4.1M | $2.2M |
| Other income (expense) | $5.8M | $6.9M |
| Total other income (expense), net | $9.8M | $9.1M |
| Net income (loss) | $22.4M | -$69.7M |
| Net income (loss) per share, basic (in dollars per share) | $0.39 | -$1.27 |
| Net income (loss) per share, diluted (in dollars per share) | $0.39 | -$1.27 |
| Weighted average common shares outstanding, basic (in shares) | 56.9M shares | 55.0M shares |
| Weighted average common share outstanding, diluted (in shares) | 57.6M shares | 55.0M shares |
| Change in unrealized (loss) gain on investments, net | $77.0K | $51.0K |
| Comprehensive income (loss) | $22.4M | -$69.6M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $21.0M | $36.4M | |
| Investments | $107.7M | $62.1M | |
| Prepaid expenses and other current assets | $3.8M | $2.6M | |
| Total current assets | $132.4M | $101.2M | |
| Property and equipment, net | $365.0K | $1.4M | |
| Restricted cash | $829.0K | $819.0K | |
| Right-of-use assets | $9.3M | $19.0M | |
| Other non-current assets | $73.0K | $249.0K | |
| Total assets | $143.0M | $122.6M | |
| Accounts payable | $579.0K | $4.0M | |
| Accrued expenses and other current liabilities | $15.2M | $16.6M | |
| Total current liabilities | $15.7M | $20.6M | |
| Non-current operating lease liability | $15.1M | $18.8M | |
| Total liabilities | $30.8M | $39.4M | |
| Commitments and contingencies (Note 12) | $0 | $0 | |
| Preferred stock, $0.0001 par value; 10,000,000 shares and 10,000,000 shares authorized at December 31, 2025 and 2024, respectively; no shares issued or outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock; $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and 500,000,000 shares authorized at December 31, 2024; 57,138,057 shares issued and outstanding at December 31, 2025 and 56,644,655 shares issued and outstanding at December 31, 2024 | $8.0K | $7.0K | |
| Additional paid-in capital | $576.8M | $570.4M | |
| Accumulated other comprehensive income (loss) | $101.0K | $24.0K | |
| Accumulated deficit | -$464.7M | -$487.1M | |
| Total stockholders' equity | $112.2M | $83.3M | $116.7M |
| Total liabilities and stockholders' equity | $143.0M | $122.6M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in shares) | 57.1M shares | 56.6M shares | |
| Common stock, shares outstanding (in shares) | 57.1M shares | 56.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | $22.4M | -$69.7M |
| Stock-based compensation expense | $6.6M | $10.6M |
| Depreciation expense | $325.0K | $343.0K |
| (Accretion) amortization on investments | -$1.3M | -$3.8M |
| Non-cash rent expense | $3.1M | $3.0M |
| Gain on sale of investments | -$74.0K | $0 |
| Impairment of right-of-use assets and property and equipment | $7.3M | $0 |
| Gain on sale of property and equipment | -$27.0K | -$94.0K |
| Prepaid expenses and other current assets | -$349.0K | $33.0K |
| Other non-current assets | $176.0K | -$249.0K |
| Accounts payable | -$3.4M | $1.7M |
| Accrued expenses and other current liabilities | -$1.4M | -$756.0K |
| Non-current operating lease liability | -$3.7M | -$3.4M |
| Net cash provided by (used in) operating activities | $29.6M | -$62.3M |
| Proceeds from disposal of equipment | $27.0K | $94.0K |
| Proceeds from sales and maturities of investments | $119.1M | $139.8M |
| Purchases of investments | -$164.0M | -$122.9M |
| Net cash provided by (used in) investing activities | -$44.9M | $17.0M |
| Proceeds from exercise of common stock options and ESPP, net of restricted stock surrendered for taxes | -$146.0K | $1.1M |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $24.5M |
| Net cash provided by (used in) financing activities | -$146.0K | $25.5M |
| Net (decrease) increase in cash and cash equivalents | -$15.4M | -$19.8M |
Compare Black Diamond Therapeutics, Inc. with another company
Former names
- Aset Therapeutics, Inc.Mar 28, 2017 to Jan 4, 20182
Recent filings
- Sep 21, 20264
- Sep 21, 20264
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jul 27, 2026SCHEDULE 13G
- Jul 8, 2026SCHEDULE 13G/A
- Jun 29, 20268-K
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 29, 20264
- Jun 22, 20264
- Jun 22, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10